GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regulus Therapeutics Inc (NAS:RGLS) » Definitions » Net Change in Cash

Regulus Therapeutics (Regulus Therapeutics) Net Change in Cash : $-0.46 Mil (TTM As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Regulus Therapeutics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Regulus Therapeutics's Net Change in Cash for the three months ended in Dec. 2023 was $-2.07 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.46 Mil.

Regulus Therapeutics Net Change in Cash Historical Data

The historical data trend for Regulus Therapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regulus Therapeutics Net Change in Cash Chart

Regulus Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.19 -3.03 29.36 -36.16 -0.46

Regulus Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.21 6.08 6.96 -11.43 -2.07

Regulus Therapeutics Net Change in Cash Calculation

Regulus Therapeutics's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-26.768+14.491+11.816+0
=-0.46

Regulus Therapeutics's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-6.125+4.932+-0.873+0
=-2.07

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regulus Therapeutics Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Regulus Therapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Regulus Therapeutics (Regulus Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regulus Therapeutics Inc (NAS:RGLS) » Definitions » Net Change in Cash
Comparable Companies
ENLV CRBP VIRX CRIS ORGS CLRB AGE MRKR CLCS AURX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
7RG0:Germany
Address
4224 Campus Point Court, Suite 210, San Diego, CA, USA, 92121
Website
https://www.regulusrx.com
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes.
Executives
Crispina Calsada officer: Chief Financial Officer C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Christopher Ray Aker officer: Sr. VP & General Counsel C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Joseph P Hagan officer: Chief Operating Officer 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Preston Klassen officer: President & Head of R & D 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Denis Drygin officer: Chief Scientific Officer 10628 SCIENCE CENTER DRIVE, SUITE 225, SAN DIEGO CA 92121
Alice Shih-hou Huang director 10628 SCIENCE CENTER DRIVE, SUITE 225, SAN DIEGO CA 92121
Ali Behbahani 10 percent owner 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Forest Baskett 10 percent owner
Joshua Makower 10 percent owner 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Paul Edward Walker director 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Carmen Chang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Scott D Sandell 10 percent owner

Regulus Therapeutics (Regulus Therapeutics) Headlines

From GuruFocus

Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates

By PRNewswire PRNewswire • 05-11-2023

Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

By PRNewswire PRNewswire • 04-12-2023

Regulus Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

By PRNewswire PRNewswire • 01-13-2023

Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates

By PRNewswire • 11-14-2023

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

By PRNewswire • 09-05-2023

Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors

By PRNewswire • 06-23-2023

Regulus Therapeutics Announces Timing for First Quarter 2022 Financial Results Webcast and Conference Call

By PRNewswire PRNewswire • 07-15-2022

Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference

By PRNewswire • 11-22-2023

Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

By PRNewswire • 10-19-2023

Regulus Therapeutics Announces Timing for Second Quarter 2022 Financial Results Webcast and Conference Call

By PRNewswire PRNewswire • 08-04-2022